期刊名称：INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology and is published four times per year. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.
Indexed / Abstracted in
Academic Search (EBSCO)
Academic Search Premier (EBSCO)
Current Abstracts (EBSCO)
EMBASE/Excerpta Medica (Elsevier)
MEDLINE/PubMed (NLM)
Science Citation Index Expanded™ (Thomson ISI)
SCOPUS (Elsevier)
Instructions to Authors
ACCEPTANCE
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor. The Editorial Board reserves the right to refuse any material for publication. Final acceptance or rejection rests with the Editorial Board.
Authors' Responsibilities
Prior to the submission of a manuscript, authors should familiarize themselves and comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals relating to:
Authorship
Conflict of interest
Protection of patients' rights to privacy
Redundant or duplicate publication
Sponsorship, authorship and accountability
Authors must also state within the Methods section of their article that:
- the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the World Medical Association's Declaration of Helsinki
- informed consent has been obtained for all investigations on human subjects (and patient anonymity has been preserved)
any experiments involving animals conform to relevant national or institutional guidelines for animal usage in research.
Failure to comply with these requirements may lead to automatic rejection of the submitted manuscript.
SUBMISSION OF MANUSCRIPTS
All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor or the Publisher reserves the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.
Covering letter Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the covering letter. Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). All investigations on human subjects must include a statement that the subject gave informed consent and patient anonymity should be preserved. Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research. Authors should declare any financial support or relationships that may pose conflict of interest.
Submission APLAR uses an electronic submission process. Please enter the website: mc.manuscriptcentral.com/aplar. If you are currently a reviewer for our Journal please email ijrd.eo@wiley.com for your Login ID and Password. If you are new to the Journal please create an author account for yourself by clicking the link on the top right hand corner of the webpage. After logging in you will be able to submit your paper by following the steps. When uploading your manuscript please note that all figures should be uploaded in separate eps or tiff files (See Figures section below). Please email ijrd.eo@wiley.com if you have any difficulties.
Copyright Papers accepted for publication become copyright of APLAR and Blackwell Publishing Asia Pty Ltd and authors will be asked to sign a transfer of copyright form. In signing the transfer of copyright it is assumed that authors have obtained permission to use any copyrighted or previously published material. All authors must read and agree to the conditions outlined in the Exclusive Licencing Form, and must sign the Form or agree that the corresponding author can sign on their behalf. Articles cannot be published until a signed Copyright Assignment Form has been received. We accept copyright forms by post, fax, and as scanned documents via email. Please submit your signed Copyright Form to:
Fotini Toso
Editorial Assistant
International Journal of Rheumatic Diseases
John Wiley & Sons (Australia) Pty Ltd
155 Cremorne Street
Richmond Victoria 3121
Australia.
Tel: (+61) 3 9247 3132; fax: (+61) 3 9274 3391; email: ijrd.eo@wiley.com
SPECIFICS FOR MANUSCRIPT SUBMISSION BY ARTICLE TYPE
Editorial: Editorials are commissioned by the Editor-in-Chief. They should contain a maximum of 2500 words with a maximum of 40 references. Abstracts can be structured or unstructured at a maximum of 250 words.
Original Article: Original Articles should reflect original work that embodies scientific excellence in rheumatology and advances in clinical research. They should contain a maximum of 4000 words (excluding Abstract, Tables, and References) and must contain a structured Abstract of 250 words or less together with a list of key words and up to 6 tables or figures and a maximum of 50 references. Divide the Abstract with the headings: Aim, Method, Results, Conclusion.
Letter to the Editor: Letters to the Editor should be no more than 1000 words with a maximum of 10 references and up to 2 figures or tables. No Abstract or key words are required.
Case Reports: The International Journal of Rheumatic Diseases has amended its Case Report section. New Case Notes/Reports will now only be considered for publication in the Letters to the Editor section. In order to suit this format, manuscripts need to be formatted as a Letter to the Editor and be approximately 1000 words in length with a maximum of 10 references. Please remove all the Abstract and all sub-headings from your manuscript prior to submission.
Review: Reviews are comprehensive analyses of specific topics. They should contain a maximum of 4000 words (excluding Abstract, Tables, and References). Reviews must contain a structured Abstract of 250 words or less and a list of key words with up to 6 tables or figures and a maximum of 50 references.
Invited Reviews: Invited Reviews are manuscripts solicited by the Editor and the Associate Editors. They should contain a maximum of 2500 words (excluding Abstract, Tables, and References). Reviews must contain a structured Abstract of 250 words or less and a list of key words.
Special Articles: They should contain a maximum of 2500 words (excluding Abstract, Tables, and References). Reviews must contain a structured Abstract of 250 words or less and a list of key words with up to 6 tables or figures and a maximum of 50 references.
GENERAL INFORMATION FOR AUTHORS FOR ALL ARTICLE TYPES
Submissions should be doubled-spaced. The top, bottom and side margins should be 30 mm. (Manuscript central numbers pages automatically) Indent new paragraphs. Turn the hyphenation option off, including only those hyphens that are essential to the meaning.
Style Manuscripts should follow the style of the Vancouver agreement detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as presented in JAMA 1997; 277: 927-34. The journal uses US spelling and authors should therefore follow the latest edition of Merriam-Webster's Collegiate Dictionary. All measurements must be given in SI units as outlined in the latest edition of Units, Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors (Royal Society of Medicine Press, London). Abbreviations should be used sparingly and only where they ease the reader's task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. Drugs should be referred to by their generic names, rather than brand names.
• Do not use the carriage return (enter) at the end of lines within a paragraph.
• Specify any special characters used to represent non-keyboard characters.
• Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for b (Greek beta).
• Use a tab, not spaces, to separate data points in tables.
• If you use a table editor function, ensure that each data point is contained within a unique cell; i.e. do not use carriage returns within cells.
• Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
Title page The title page should contain (i) the title of the paper (do not use abbreviations in title), (ii) the full names of the authors and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript, proofs and requests for offprints should be sent. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified. The title should be short, informative and contain the major key words. A short running title (less than 40 characters, including spaces) should also be provided.
Acknowledgments The source of financial grants and other funding should be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not allowed.
References The Vancouver system of referencing should be used. In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited only in tables or figure legends, number them according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in order of appearance in the text. Cite the names of all authors when there are six or less; when seven or more list the first three followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should appear in the text only. References should be listed in the following form.
Journal article: Needleman P, Isakson PC (1997) The discovery and function of COX-2. J Rheumatol 24,6-7.
Book: Munthe E (ed.) The Care of Rheumatic Children. European League Against Rheumatism, Basel, Switzerland.
Chapter in a book: Croft P (1993) Soft tissue rheumatism. In: AJ Silman, MC Hochberg (eds) Epidemiology of the Rheumatic Diseases, pp. 375-421. Oxford University Press, Oxford.
Tables Tables should be self-contained and complement, but not duplicate, information contained in the text. Tables should be numbered consecutively in Arabic numerals. Each table should be presented on a separate page with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. The table and its legend/footnotes should be understandable without reference to the text.
Figures All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Image files should be supplied as high resolution (at least 300 d.p.i.) files, saved as .eps or .tif format and uploaded separately in your Manuscript Central submission with each file labelled "Figure 1, Figure 2" etc. When uploading your documents into Manuscript Central please note that the "Supplemental File" file designation is not seen by reviewers.
Color figures A charge of US$530 for the first three color figures and US$265 for each extra color figure thereafter will be charged to the author.
Figure legends Legends should be self-explanatory and placed at the end of your main document. The legend should incorporate definitions of any symbols used and all abbreviations and units of measurement should be explained so that the figure and its legend are understandable without reference to the text. (State copyright authorization if figures have been reproduced from another source.)
PROOFS
It is essential that corresponding authors supply an email address to which correspondence can be emailed while their article is in production. Word files of edited articles will be sent for checking via email, and should be returned to the Publisher. It is essential that these files are checked carefully, as the cost of changes made at a later stage may be charged to the author. Full instructions on how to correct and return the file will be attached to the email. Notification of the URL from where to download a Portable Document Format (PDF) typeset page proof, associated forms and further instructions will be sent by email to the corresponding author. The purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the essential correction of errors are unacceptable at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated; otherwise, it may be signed off on by the Editor or held over to the next issue.
OFFPRINTS
Free access to the final PDF offprint of your article will be available via author services. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.
BLACKWELL JOURNALS ONLINE
Visit the International Journal of Rheumatic Diseases home page at http:// www.blackwellpublishing.com/ijrd for more information, and Blackwell Publishing's web pages for submission guidelines and digital graphics standards at http://www.blackwellpublishing.com/bauthor/ journal.asp and http://www.blackwellpublishing.com/bauthor/ digill.asp. International Journal of Rheumatic Diseases is also available online via Wiley Interscience at www.interscience.wiley.com.
Editorial Board
Editor-in-Chief
CS Lau, University of Hong Kong, Hong Kong, China
Senior Editors
D Danda, Christian Medical College and Hospital, Vellore, India
K Lim, Western Hospital and St Vincents Hospital, Melbourne, Australia
SV Navarra, University of Santo Tomas, Manila, Philippines
K Pile, University of Western Sydney, Sydney, Australia
Associate Editors
F Davatchi, Tehran University for Medical Sciences, Tehran, Iran
KY Fong, Singapore General Hospital, Singapore
SA Haq, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Bangladesh
ZG Li, Peking University People's Hospital, Beijing, China
HY Lin, Taipei Veterans General Hospital, Taipei, Taiwan
A Mak, National University Hospital, National University of Singapore, Singapore
MY Mok, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
N Shen, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
K Torralba, Keck School of Medicine, University of Southern California, Los Angeles, USA
S Whittle, The Queen Elizabeth Hospital, Adelaide, Australia
DH Yoo, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea
Editorial Board
H Badsha, Tan Tock Seng Hospital, Singapore
P Brooks, University of New South Wales, St Vincent's Hospital, Sydney, Australia
HH Chng, Tan Tock Seng Hospital, Singapore
A Chopra, Center for Rheumatic Diseases, Pune, India
CT Chou, Taipei Veterans General Hospital, TaiPei, Taiwan
P Ghosh, University of Sydney, Sydney, Australia
JR Gu, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
AY Gasparyan, Russell's Hall Hospital, West Midlands, United Kingdom
R Handa, All India Institute of Medical Sciences, New Delhi, India
F Huang, Chinese PLA General Hospital,Beijing, China
Ou Jin, 3rd Hospital of Sun Yat-san University, Guang Zhou, P.R.China
H Kalim, Medical Faculty of Brawijaya University - Dr Saiful Anwar Hospital, Malang, Indonesia
HY Kim, The Catholic University of Korea, Kang-Nam St Mary's Hospital, Seoul, Korea
ET Koh, Tan Tock Seng Hospital, Singapore
EMC Lau, Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China
KH Leong, Gleneagles Medical Centre, Singapore
AN Malaviya, A&R Clinic for Arthritis and Rheumatism, New Delhi, India
CC Mok, Tuen Mun Hospital, Hong Kong, China
C Morimoto, University of Tokyo,Tokyo, Japan
K Nishioka, St. Marianna University School of Medicine, Kawasaki,Japan
S Ozgocmen, Erciyes University, Kayseri, Turkey
J Petrie, QE Health, Rotorua, New Zealand
J Thumboo, Singapore General Hospital, Singapore
S Vasoo, National University Hospital, Singapore
U Visitsunthorn, Mahidol University, Salaya,Thailand
JCC Wei, Chung Shan Medical University Hospital, Taichung, Taiwan
SS Yeap, University of Malaya, Kuala Lumpur, Malaysia
FC Zhang, Peking Union Medical College Hospital, Beijing, China
APLAR Advisory Board
NM Ahmad
CM Amante
TN An
DE Caughey
DM Chang
SL Chen
Y Dong
PH Feng
E Li
KD Muirden
I Nagaya
AR Nasution
PK Pispati
CH Tay
TP Torralba
M Vatanasuk
K Veerapen
RD Wigley
RWS Wong
International Advisory Panel
CM Black, UK
R Cervera, Spain
EHY Choy, UK
PT Fan, USA
MJ Fritzler, Canada
RI Fox, USA
GRV Hughes, UK
JR Kalden, Germany
MA Khan, USA
RG Lahita, USA
TJA Lehman, USA
MH Liang, USA
L van de Putte, The Netherlands
HR Schumacher Jr, USA
Y Shoenfeld, Israel
RD Sturrock, UK
BP Tsao, USA
MB Urowitz, Canada
ZN Yin, USA
CY Yu, USA
DTY Yu, USA
|
